INCY - Incyte Corp Stock Price, Fair Value and News

53.50USD-0.87 (-1.60%)Market Closed

Market Summary

USD53.50-0.87

Market Closed

-1.60%

INCY Alerts

Big jump in Earnings (Y/Y)

INCY Stock Price

View Fullscreen

INCY RSI Chart

INCY Valuation

Market Cap

12.0B

Price/Earnings (Trailing)

16.12

Price/Sales (Trailing)

3.19

EV/EBITDA

7.83

Price/Free Cashflow

14.63

INCY Price/Sales (Trailing)

INCY Profitability

Operating Margin

93.12%

EBT Margin

27.03%

Return on Equity

13.82%

Return on Assets

10.45%

Free Cashflow Yield

6.83%

INCY Fundamentals

INCY Revenue

Revenue (TTM)

3.8B

Rev. Growth (Yr)

8.93%

Rev. Growth (Qtr)

-13.07%

INCY Earnings

Earnings (TTM)

745.4M

Earnings Growth (Yr)

681.22%

Earnings Growth (Qtr)

-15.68%

Breaking Down INCY Revenue

Last 7 days

1.1%

Last 30 days

-2.8%

Last 90 days

-6.7%

Trailing 12 Months

-17.4%

How does INCY drawdown profile look like?

INCY Financial Health

Current Ratio

3.47

Debt/Equity

Debt/Cashflow

45.4

INCY Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

3.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.8B	0	0	0
2023	3.5B	3.5B	3.6B	3.7B
2022	3.1B	3.3B	3.3B	3.4B
2021	2.7B	2.7B	2.9B	3.0B
2020	2.2B	2.4B	2.5B	2.7B
2019	2.0B	2.0B	2.1B	2.2B
2018	1.5B	1.7B	1.8B	1.9B
2017	1.2B	1.3B	1.4B	1.5B
2016	857.9M	941.2M	1.0B	1.1B
2015	581.0M	644.4M	633.8M	753.8M
2014	373.7M	371.6M	484.6M	511.5M
2013	332.0M	347.1M	371.7M	354.9M
2012	98.7M	168.4M	212.1M	297.1M
2011	184.6M	151.5M	151.4M	94.5M
2010	49.4M	89.6M	129.7M	169.9M
2009	0	0	0	9.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Incyte Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	baker bros. advisors lp	acquired	-	-	1,086	-
Mar 28, 2024	clancy paul j	acquired	22,958	56.97	403	-
Mar 28, 2024	harrigan edmund	acquired	23,528	56.97	413	-
Mar 25, 2024	trotta matteo	acquired	-	-	7,828	evp, gm, dermatology us
Feb 14, 2024	hoppenot herve	acquired	-	-	41,577	chairman / ceo
Feb 14, 2024	stamoulis christiana	acquired	-	-	7,377	evp & chief financial officer
Feb 14, 2024	swain paula j	acquired	-	-	7,377	evp, human resources
Feb 14, 2024	flannelly barry p	acquired	-	-	7,377	evp & general manager us
Feb 14, 2024	stein steven h	acquired	-	-	7,377	evp & chief medical officer
Feb 14, 2024	iyengar vijay k	acquired	-	-	7,377	evp, gmapps

Which funds bought or sold INCY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	MEEDER ASSET MANAGEMENT INC	new	-	27,687	27,687	-%
May 07, 2024	ClariVest Asset Management LLC	added	100	410	912	-%
May 07, 2024	Smithfield Trust Co	unchanged	-	-	7,000	-%
May 07, 2024	Arizona State Retirement System	added	0.09	-302,114	2,984,940	0.02%
May 07, 2024	Inspire Investing, LLC	added	17.3	113,876	1,885,960	0.19%
May 07, 2024	ASSETMARK, INC	added	12.73	76,005	3,402,300	0.01%
May 07, 2024	Applied Finance Capital Management, LLC	new	-	16,997,400	16,997,400	1.20%
May 07, 2024	FORSTA AP-FONDEN	added	164	2,725,050	4,671,540	0.04%
May 07, 2024	Cornerstone Planning Group LLC	sold off	-100	-63.00	-	-%
May 07, 2024	WestEnd Advisors, LLC	unchanged	-	-17.00	171	-%

Are Funds Buying or Selling INCY?

Are funds buying INCY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INCY

No. of Funds

INCY Alerts

Big jump in Earnings (Y/Y)

Unveiling Incyte Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	dodge & cox	7.2%	16,090,421	SC 13G/A
Feb 13, 2024	vanguard group inc	10.05%	22,519,381	SC 13G/A
Jan 24, 2024	blackrock inc.	10.8%	24,297,249	SC 13G/A
Dec 08, 2023	vanguard group inc	10.02%	22,466,463	SC 13G/A
Jun 08, 2023	blackrock inc.	10.5%	23,468,952	SC 13G/A
Mar 15, 2023	baker bros. advisors lp	16.3%	36,280,967	SC 13D/A
Feb 14, 2023	dodge & cox	8.7%	19,362,935	SC 13G/A
Feb 09, 2023	vanguard group inc	9.68%	21,533,818	SC 13G/A
Jan 25, 2023	blackrock inc.	8.9%	19,836,617	SC 13G/A
Mar 10, 2022	baker bros. advisors lp	16.4%	36,269,307	SC 13D/A

Recent SEC filings of Incyte Corp

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 27, 2024	3	Insider Trading
Mar 27, 2024	4	Insider Trading

Peers (Alternatives to Incyte Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Incyte Corp News

Latest updates

Incyte Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-13.1%	881	1,013	919	955	809	927	823	911	733	863	813	706	605	790	621	688	569	579	552	530	498
Cost Of Revenue	-12.6%	61.00	70.00	60.00	68.00	57.00	59.00	55.00	51.00	43.00	44.00	40.00	38.00	29.00	36.00	34.00	33.00	27.00	32.00	30.00	29.00	23.00
Costs and Expenses	-4.5%	789	826	704	761	784	857	685	657	617	752	578	565	506	625	615	457	1,233	484	417	431	424
S&GA Expenses	2.2%	300	294	268	284	316	273	266	253	210	226	191	169	154	167	121	118	111	136	103	106	124
R&D Expenses	-3.4%	429	444	376	401	407	501	384	347	353	-	335	344	307	406	438	287	1,085	313	281	289	271
EBITDA Margin	18.0%	0.29*	0.25*	0.20*	0.18*	0.17*	0.18*	0.19*	0.21*	0.20*	0.21*	0.23*	0.17*	-	-	-	-	-	-	-	-	-
Interest Expenses	-46.5%	0.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
Income Taxes	-4.7%	67.00	70.00	63.00	74.00	30.00	52.00	36.00	68.00	33.00	-443	28.00	22.00	16.00	18.00	12.00	17.00	17.00	15.00	20.00	3.00	2.00
Earnings Before Taxes	-12.8%	236	271	234	278	52.00	81.00	149	229	71.00	120	209	172	69.00	168	-3.51	307	-704	126	148	109	104
EBT Margin	19.8%	0.27*	0.23*	0.18*	0.16*	0.15*	0.16*	0.17*	0.19*	0.18*	0.19*	0.21*	0.15*	-	-	-	-	-	-	-	-	-
Net Income	-15.7%	170	201	171	204	22.00	28.00	113	161	38.00	564	182	149	54.00	150	-15.20	290	-720	111	128	105	102
Net Income Margin	22.3%	0.20*	0.16*	0.12*	0.10*	0.09*	0.10*	0.26*	0.28*	0.30*	0.32*	0.18*	0.12*	-	-	-	-	-	-	-	-	-
Free Cashflow	48.1%	219	148	148	307	-105	284	296	174	216	115	255	173	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	5.2%	7,136	6,782	6,388	6,208	5,798	5,841	5,510	5,319	5,054	4,933	4,199	3,905	3,661	3,561	3,307	3,212	2,752	3,427	3,215	2,948	2,754
Current Assets	4.4%	4,849	4,645	4,403	4,264	3,972	4,093	3,821	3,626	3,288	3,119	2,924	2,620	2,450	2,360	2,159	2,078	1,716	2,481	107	2,059	1,905
Cash Equivalents	4.1%	3,346	3,213	3,227	3,131	2,823	2,953	2,692	2,437	2,258	2,059	2,001	1,799	1,672	1,515	1,500	1,329	1,046	1,834	1,703	1,417	1,301
Inventory	1.1%	64.00	63.00	57.00	36.00	41.00	42.00	46.00	55.00	36.00	28.00	21.00	17.00	17.00	16.00	17.00	16.00	14.00	11.00	7.00	7.00	7.00
Net PPE	-4.2%	720	752	733	749	742	739	716	721	729	724	687	661	595	560	498	454	410	378	347	339	338
Goodwill	0%	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156
Liabilities	9.4%	1,741	1,592	1,457	1,468	1,335	1,471	1,284	1,234	1,191	1,163	1,050	969	934	950	917	868	815	828	792	700	669
Current Liabilities	12.6%	1,396	1,240	1,125	1,119	1,006	1,157	1,007	927	886	854	743	660	624	631	606	557	503	513	133	367	365
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.00	18.00	18.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00	19.00	19.00	18.00	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.00	18.00	18.00
Shareholder's Equity	3.9%	5,394	5,190	4,931	4,741	4,463	4,370	4,227	4,085	3,863	3,770	3,149	2,936	2,728	2,611	2,391	2,345	1,938	2,598	2,423	2,247	2,086
Retained Earnings	105.7%	330	160	-40.69	-211	-415	-437	-465	-578	-739	-777	-1,341	-1,523	-1,672	-1,726	-1,876	-1,861	-2,151	-1,430	-1,541	-1,670	-1,775
Additional Paid-In Capital	1.1%	5,070	5,016	4,949	4,926	4,857	4,792	4,721	4,689	4,626	4,567	4,509	4,477	4,421	4,353	4,277	4,218	4,102	4,044	3,973	3,926	3,870
Shares Outstanding	0.1%	225	224	224	223	223	223	222	222	221	220	220	220	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	11,700	-	-	-	14,200	-	-	-	16,000	-	-	-	19,100	-	-	-	15,400	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	48.1%	218,811	147,729	147,835	306,526	-105,603	283,662	296,381	174,157	215,741	115,351	255,098	172,944	206,095	107,321	182,115	269,382	-683,417	131,618	270,415	152,960	155,663
Share Based Compensation	-0.4%	59,778	59,990	48,000	54,520	53,379	52,679	45,404	46,496	43,841	48,222	42,694	44,732	47,358	45,261	43,800	46,303	42,513	42,023	43,359	40,615	40,592
Cashflow From Investing	52.7%	-73,112	-154,500	-17,189	-7,429	-28,559	-20,912	-28,402	-12,480	-16,748	-66,047	-32,754	-49,145	-59,753	-102,730	-14,453	-43,258	-108,560	-30,028	12,284	-45,147	-24,563
Cashflow From Financing	-3687.6%	-12,413	346	-37,256	12,868	4,009	-2,480	-14,311	15,901	96.00	9,005	-19,343	3,679	12,835	11,872	931	56,407	2,499	29,320	2,894	9,010	4,487

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INCY Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 880,889	$ 808,673
Costs, expenses and other:
Cost of product revenues (including definite-lived intangible amortization)	60,956	56,822
Research and development	429,260	406,641
Selling, general and administrative	300,256	315,606
(Gain) loss on change in fair value of acquisition-related contingent consideration	(456)	6,196
(Profit) and loss sharing under collaboration agreements	(1,025)	(1,362)
Total costs, expenses and other	788,991	783,903
Income from operations	91,898	24,770
Interest income and other, net	44,744	32,873
Interest expense	(430)	(469)
Unrealized gain (loss) on long term investments	99,947	(5,318)
Income before provision for income taxes	236,159	51,856
Provision for income taxes	66,611	30,153
Net income	$ 169,548	$ 21,703
Net income per share:
Basic (in USD per share)	$ 0.76	$ 0.10
Diluted (in USD per share)	$ 0.75	$ 0.10
Shares used in computing net income per share:
Basic (in shares)	224,484	222,960
Diluted (in shares)	227,219	225,589
Product revenues, net
Revenues:
Total revenues	$ 729,923	$ 693,237
Product royalty revenues
Revenues:
Total revenues	125,966	115,436
Milestone and contract revenues
Revenues:
Total revenues	$ 25,000	$ 0

INCY Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

^[1]

Current assets:

Cash and cash equivalents

$ 3,346,204

$ 3,213,376

Marketable securities—available-for-sale (amortized cost $506,379 and $442,816 as of March 31, 2024 and December 31, 2023, respectively; allowance for credit losses $0 as of March 31, 2024 and December 31, 2023)

504,484

442,667

Accounts receivable

745,526

743,557

Inventory

63,642

62,972

Prepaid expenses and other current assets

189,235

182,830

Total current assets

4,849,091

4,645,402

Restricted cash

1,627

1,845

Long term investments

287,663

187,716

Inventory

264,292

206,965

Property and equipment, net

719,999

751,513

Finance lease right-of-use assets, net

25,533

25,535

Other intangible assets, net

117,841

123,545

Goodwill

155,593

Deferred income tax asset

666,566

631,886

Other assets, net

47,400

52,107

Total assets

7,135,605

6,782,107

Current liabilities:

Accounts payable

164,238

109,601

Accrued compensation

89,109

153,348

Accrued and other current liabilities

1,102,268

935,569

Finance lease liabilities

3,678

3,439

Acquisition-related contingent consideration

37,160

38,422

Total current liabilities

1,396,453

1,240,379

Acquisition-related contingent consideration

164,840

173,578

Finance lease liabilities

28,934

29,162

Other liabilities

151,107

149,151

Total liabilities

1,741,334

1,592,270

Commitments and contingencies (Note 15)

Stockholders’ equity:

Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding

Common stock, $0.001 par value; 400,000,000 shares authorized; 224,533,449 and 224,286,862 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively

224

Additional paid-in capital

5,070,286

5,016,122

Accumulated other comprehensive (loss) income

(6,172)

13,106

Retained earnings

329,933

160,385

Total stockholders’ equity

5,394,271

5,189,837

Total liabilities and stockholders’ equity

$ 7,135,605

$ 6,782,107

[1]	The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date.

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

CEO	Mr. Herve Hoppenot
WEBSITE	incyte.com
INDUSTRY	Biotechnology
EMPLOYEES	2324

Incyte Corp Frequently Asked Questions

What is the ticker symbol for Incyte Corp? What does INCY stand for in stocks?

INCY is the stock ticker symbol of Incyte Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Incyte Corp (INCY)?

As of Wed May 08 2024, market cap of Incyte Corp is 12.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INCY stock?

You can check INCY's fair value in chart for subscribers.

What is the fair value of INCY stock?

You can check INCY's fair value in chart for subscribers. The fair value of Incyte Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Incyte Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INCY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Incyte Corp a good stock to buy?

The fair value guage provides a quick view whether INCY is over valued or under valued. Whether Incyte Corp is cheap or expensive depends on the assumptions which impact Incyte Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INCY.

What is Incyte Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, INCY's PE ratio (Price to Earnings) is 16.12 and Price to Sales (PS) ratio is 3.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INCY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Incyte Corp's stock?

In the past 10 years, Incyte Corp has provided 0.003 (multiply by 100 for percentage) rate of return.